correlation of serum thymidine kinase in the prognosis/treatment of cancer
DESCRIPTION
Correlation of Serum Thymidine Kinase in the Prognosis/Treatment of Cancer By: Danielle Cervantes. Thymidine Kinase A transferase enzyme that catalyzes phosphorylation of drugs into a form that will be active against viruses. Dot Blot Assay - PowerPoint PPT PresentationTRANSCRIPT
Correlation ofSerum Thymidine Kinase
in thePrognosis/Treatment of
Cancer
By: Danielle Cervantes
Thymidine Kinase
A transferase enzyme that catalyzes phosphorylation of drugs into a form that will be active against viruses.
Dot Blot Assay
Technique similar to Western Blotting that involves separating proteins by spotting through a circular template directly onto the cell membrane.
Receiver Operating Characteristic
An analytical test that determines the specificity and selectivity of a medical test.
Specificity
Odds that a test will be negative in the absence of a disease
Selectivity
Odds that a test will be positive in the presence of a disease
Non-Hodgkin's Lymphoma Is a class of cancers that
affect the white blood cells
Can be aggressive or indolent
Estimated New Cases & Deaths in US in 2010
Cases: 65,540 Deaths: 21,210
cancer.osu.edu
STK1 as a Prognostic Factor
Used in prognosis after chemotherapy treatment Levels were determined by chemiluminescent
dot-blot assay Before chemo, and 1 & 28 days after
STK1 levels were analyzed two ways 1) Western blot using an anti-TK1 IgY antibody
2) Receiver Operating Characteristic (ROC) analysis
STK1 as a Prognostic Factor Results Mean STK1 levels were much higher in patients
with non-Hodgkin's lymphoma than in healthy people
Levels decreased until at day 28 the level corresponded with that of a healthy person
The mean of the STK1 levels was significantly correlated with the clinical response and 5-year survival rate
Electrochemiluminescence (ECL) Assay
Designed to detect biological threats
antigen complexes with 2 antibodies
1) attached to a magnetic particle
2) modified with a reporter molecule
Electrode attracts magnetic particle and the detector emits light.
Measured light is correlated with presence of antigenlabautopedia.org
Complete Response (Complete Remission)
Disappearance of all signs of cancer after treatment
Partial Response (Partial Remission)
Decrease in size of tumor or extent of cancer after treatment
Stable Disease
Cancer that is not increasing or decreasing in extent/severity
Progressive Disease
Cancer that's growing/spreading/getting worse
Metastasis
Process of cancer spreading from first location to another.
Cancer resulting from the spread of the primary tumor
STK1 in Cancer Treatment
Experiment examined significance of STK1 in clinical settings
Monitored 1,247 patients Concentration of STK1 was determined by ECL
assay Value was correlated to clinical stage & reaction Monitored outcome of surgery/multi-drug chemo
Looked at 5 different carcinomas Lung, esophagus, gastric, head & neck, & thyroid
Results STK1 values correlated with clinical stage in 4 of 5
carcinomas Levels declined in all tumor groups after treatment In CR or PR patients levels decreased or were <2pM In SD or PD patients levels increased or were >2pM
Some showed metastasis Overall STK1 correlates to clinical stages and reactions. It
also monitors effectiveness of therapies in controlled/routine clinical trials
Overall Results STK1 is a good indicator as to the presence of
non-Hodgkin's lymphoma in patients STK1 is a good indicator of the effectiveness of
treatment of different carcinomas It is not a good indicator of the effectiveness of
treatment in head & neck carcinomas
Significance of Results The results of these two studies show that levels of
STK1 can be used as a prognostic and monitoring factor in cancer. This means that more invasive/expensive procedures can be omitted in treatment.
References "Serum Thymidine Kinase 1 Correlates to Clinical Stages and Clinical
Reactions and Monitors the Outcome of Therapy of 1,247 Cancer Patients in Routine Clinical Settings."
http://www.cancer.gov
http://www.antibodybeyond.com/applications/dotblot.htm
"Electrochemiluminescence (ECL) Assay." <www.jpeocbd.osd.mil/packs/DocHandler.ashx?DocID=8597>.
http://www.cancer.gov/cancertopics/types/non-hodgkin
"Serum Thymidine Kinase 1 Concentration as a Prognostic Factor of Chemotherapy-treated Non-Hodgkin's Lymphoma Patients."
http://www.medcalc.be/manual/roc.php